FDA: Evusheld may not prevent COVID-19 caused by certain variants 

The COVID-19 monoclonal antibody therapy Evusheld may not prevent COVID-19 caused by certain variants of the virus, the Food and Drug Administration announced this week. For details, see the updated fact sheet for health care providers. 
 
FDA last year authorized the combination monoclonal antibody therapy for emergency use to help prevent COVID-19 in certain adults and children with compromised immune systems or a history of severe adverse reaction to a COVID-19 vaccine or its components. FDA continues to recommend Evusheld to prevent COVID-19 as it still offers protection against many circulating variants, but encourages patients to be prepared to test and seek immediate treatment if they experience COVID-19 symptoms. The agency also continues to recommend that people who can get vaccinated and boosted to prevent COVID-19.